Since 2024: Glaring Reality Keeps AbbVie on Hold
AbbVie’s stock has climbed since 2024, yet a stubborn balance sheet and looming biosimilar erosion create a cautious ...
Curious about what you can buy with credit card points? Explore a variety of exciting options to make the most of your rewards!
28,188 articlesAbbVie’s stock has climbed since 2024, yet a stubborn balance sheet and looming biosimilar erosion create a cautious ...
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Palantir Technologies has delivered a staggering 625% rally since 2020, but a mix of government ties and governance s...
As inflation runs hot and rate prospects swing, retail investors nod to inflation-defensive plays. Smithfield Foods a...
In the month since THYP debuted on Nasdaq, hype etfs quietly pulled $161 million in net inflows across the three US-t...
Fermi America slumped 11.5% as it unveiled a $375 million convertible note offering and reported a Q1 with zero reven...
Uber unveils a multiyear pact to invest up to $1.25 billion in Rivian, aiming to roll out up to 50,000 autonomous Riv...
KeyBanc boosted its outlook on CrowdStrike, lifting the price target to $700 after signals from the Mythos conference...
Private reverse mortgage products are outpacing HECMs, underscoring a broader push to revive the HECM for Purchase. I...
Mega-cap tech now drives most S&P 500 gains, leaving the rest of the market with thinner support. Here’s what investo...
As Berkshire transitions to Greg Abel, Warren Buffett’s final investment points to a return to era-defining brands. T...
Energy costs are climbing in early 2026 and are expected to ripple through U.S. supply chains, pressuring prices on g...